To editor:Thrombophilia is a group of blood clotting disorders that increase the risk of venous thromboembolism(VTE),which is primarily caused by genetic mutations in proteins involved in the coagulation cascade.These...To editor:Thrombophilia is a group of blood clotting disorders that increase the risk of venous thromboembolism(VTE),which is primarily caused by genetic mutations in proteins involved in the coagulation cascade.These mutations include Factor V Leiden,prothrombin G20210A,protein S deficiency(PSD),antithrombin III deficiency,and methyltetrahydrofolate reductase.Among these,PSD contribute to a significant proportion of thromboembolic events in pregnant women,particularly in those with additional risk factors such as obesity,advanced maternal age,or a history of VTE.1 This correspondence aims to present a series of clinical cases of PSD in pregnant women,highlighting treatment strategies,especially in a hospital in a low-and middle-income country(LMIC)with limited access to advanced therapeutic options.Written informed consent was obtained from all patients involved in this study.We had treated six pregnant women diagnosed with PSD.Among these cases,four had a history of adverse obstetric outcomes,including abortion,preterm birth,or intrauterine fetal death,while the other two cases had recurrent miscarriages(Supplementary Table 1,http://links.lww.com/MFM/A72).These women were identified after the diagnosis of PSD,and each case was carefully monitored throughout pregnancy.展开更多
文摘To editor:Thrombophilia is a group of blood clotting disorders that increase the risk of venous thromboembolism(VTE),which is primarily caused by genetic mutations in proteins involved in the coagulation cascade.These mutations include Factor V Leiden,prothrombin G20210A,protein S deficiency(PSD),antithrombin III deficiency,and methyltetrahydrofolate reductase.Among these,PSD contribute to a significant proportion of thromboembolic events in pregnant women,particularly in those with additional risk factors such as obesity,advanced maternal age,or a history of VTE.1 This correspondence aims to present a series of clinical cases of PSD in pregnant women,highlighting treatment strategies,especially in a hospital in a low-and middle-income country(LMIC)with limited access to advanced therapeutic options.Written informed consent was obtained from all patients involved in this study.We had treated six pregnant women diagnosed with PSD.Among these cases,four had a history of adverse obstetric outcomes,including abortion,preterm birth,or intrauterine fetal death,while the other two cases had recurrent miscarriages(Supplementary Table 1,http://links.lww.com/MFM/A72).These women were identified after the diagnosis of PSD,and each case was carefully monitored throughout pregnancy.
